Meet Our Team

Management

Nelson Whistance
President & CEO

Bill Malecki
COO & CTO

Paul Russo
VP of Sales

Tara Murphy
VP of Marketing

Rob McCarthy
VP of Manufacturing

Edward Yu
EEVP of Regulatory, Clinical & Medical Affairs and QA

Robert Brown
CFO

Board

Mortimer (Tim) Berkowitz
Co-founder & Managing Partner,
InnovaHealth Partners, LP

Nelson Whistance
President & CEO

John Tullis
Managing Partner, Tullis Health Investors

John McCormick
Partner & Founder, InnovaHealth Partners, LP

Skip Baldino
Board Member

Heather Knight
Board Member

Barbara Levy, M.D., FACOG, FACS
Board Advisor

Lisa Garrett
Board Member

Medical Advisors

Barbara Levy, M.D., FACOG, FACS
Medical Advisor

Andrew I. Brill, M.D.
Medical Advisor

Important Safety Information

Cerene® Cryotherapy Device is indicated to ablate the endometrial lining of the uterus in premenopausal women with heavy menstrual bleeding due to benign causes for whom childbearing is complete. Pregnancy following the Cerene procedure can be dangerous; therefore, contraception must be used until menopause. The Cerene procedure is not for those who have or suspect uterine cancer; have an active genital, urinary or pelvic infection; or an IUD. There are risks and considerations associated with the use of the Cerene Cryotherapy Device. Temporary side effects may include uterine cramping, vaginal infection, and lightheadedness. For detailed benefit and risk information, consult the Cerene Instructions for Use (IFU) or your healthcare professional. CAUTION: Federal (USA) law restricts this device to sale by or on the order of a physician trained in the use of the Cerene Cryotherapy Device. Learn More
CC-26-0306

Patients
Healthcare Professionals
Company
News

Resources

Contact Us
S afety Information

Copyright 2026 Channel Medsystems Inc.